Vir Biotechnology Raises $150M in Public Stock Offering
Event summary
- Vir Biotechnology priced a public offering of 17,647,058 shares of common stock at $8.50 per share, raising $150M before expenses.
- The offering includes a 30-day option for underwriters to purchase an additional 2,647,058 shares.
- Closing of the offering is expected on February 27, 2026, subject to customary conditions.
- The shares are being offered under an automatically effective shelf registration statement on Form S-3 filed in November 2023.
The big picture
Vir Biotechnology's $150M public offering reflects the ongoing need for biopharmaceutical companies to secure substantial capital to fund clinical trials and development programs. The move comes amid a competitive landscape where firms are racing to bring innovative treatments for serious infectious diseases and cancer to market. The involvement of major underwriters like Goldman Sachs and Barclays underscores the strategic importance of this financing round in supporting Vir's long-term growth ambitions.
What we're watching
- Capital Deployment
- How Vir Biotechnology will allocate the $150M proceeds to advance its clinical-stage portfolio in infectious diseases and cancer.
- Market Performance
- Whether the additional shares sold under the underwriters' option will impact the company's stock price post-offering.
- Clinical Progress
- The pace at which Vir Biotechnology can translate its PRO-XTEN® dual-masked T-cell engagers into commercial successes.
Related topics